ERBB2 and ductal breast carcinoma in situ: Together, these observations reflect the heterogeneity of the samples and are consistent with the literature that ERBB2 is overexpressed in 30 to 35% of DCIS, while ERBB2 is only expressed in 15 to 25% of IBC (46–49).